Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?
This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
Introduction
Multiple Sclerosis: Clinical Subtypes
Progressive Disease: Overlapping Subtypes?
Radiologically Isolated Syndrome and Risk of MS
Proportion of Patients With SPMS and Other MS Phenotypes
Need to Detect Disease Activity and Disease Progression: Criteria for Progressive MS Phenotypes
Diagnosing SPMS: Input From Patients
Age of Onset of SPMS
Two Components of SMPS as Targets for Treatment
Long-Term Follow-Up on DMT Use: Conversion to SPMS
Recent RCTs in SPMS: Negative for Primary Endpoints
Recent RCTs in SPMS: Positive for Primary Endpoints
Understanding the Pathophysiology of Progressive MS: Potential Treatment Targets
Phase 3 Study of Siponimod: Reduced Risk of Disability Progression
Subgroup Analyses of Phase 3 Study of Siponimod: Risk of Disability Progression at 6 Months
Siponimod in SPMS Shows Distinct Results From Fingolimod in PPMS
S1P Receptor Gene Expression
Randomized, Double-Blind, Placebo-Controlled Study of Biotin in PPMS and SPMS
Extension Phase Results With Biotin: Improvement After Switch From Placebo
Phase 2 Results for High-Dose Simvastatin and Brain Atrophy Reduction in SPMS: MS-STAT
Effect of High-Dose Simvastatin on Cognitive Measures: MS-STAT Cognitive Substudy
Analysis of the Potential Effect of Lipid-Lowering on Disability Reduction With Simvastatin
Phase 2 Study of Ibudilast in PPMS and SPMS
Main Safety Findings With Ibudilast
Ibudilast: Background and Mechanism of Action
MS-SMART: Multiarm Trial Design
PPMS and SPMS as One Entity in Clinical Trials? Clinician Perspectives
Concluding Remarks I
Concluding Remarks II
Abbreviations
Abbreviations (cont)